Charles River Introduces CliniPrime Cryopreserved Leukopaks, Expanding Suite of GMP-Compliant Cellular Products
16 Novembro 2023 - 10:00AM
Business Wire
New option for cryopreserved leukopaks supports
demand of gene-modified cell therapy development and
manufacturing
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced the expansion of its CliniPrime™ suite of Good
Manufacturing Practice (GMP)-compliant offerings with the launch of
CliniPrime Cryopreserved Leukopaks for cell therapy development and
manufacturing. All CliniPrime products meet regulatory guidelines
for clinical trial development and commercial manufacturing of
advanced therapies.
As advances in gene-modified cell therapies continue, there is a
growing need for reliable and consistent sources of GMP-compliant,
donor-derived, cellular starting material. Cryopreserved leukopaks
play a critical role in the research and development continuum and
have become an ideal option for many cell therapy developers.
Cryopreservation shortly after leukopak collection maximizes
cellular viability, product consistency, and long-term
availability. These factors can help simplify logistics and
mitigate risk throughout the supply chain of donor-derived cellular
starting materials.
The launch of CliniPrime Cryopreserved Leukopaks completes an
already robust portfolio of GMP-compliant leukopaks from Charles
River. CliniPrime leverages Charles River’s established production
processes to provide advanced therapy programs with a high-quality
product offering that supports both clinical trial development and
commercialization, while reducing client resource investment and
risk.
Charles River provides cellular products and services, creating
collaborative relationships with clients as they progress their
programs through the development cycle.
Approved Quotes
- “The new CliniPrime Cryopreserved Leukopak offering provides a
solution to a growing industry need for reliable and consistent
sources of cellular starting material. Clients can rely on Charles
River leukopaks as they develop potentially life-saving modalities
of treatment.” – Birgit Girshick, Executive Vice President and
Chief Operating Officer, Charles River
- “The addition of the cryopreserved leukopak rounds out the
CliniPrime suite of GMP-compliant offerings. Clients now have rapid
access to fresh or cryopreserved leukopaks to meet any specific
program needs.” – Steve Phagoo, Executive Director, Global Cell
Solutions, Charles River
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231116867976/en/
Investor Contact: Todd Spencer Corporate Vice President,
Investor Relations 781.222.6455 todd.spencer@crl.com
Media Contact: Amy Cianciaruso Corporate Vice President,
Chief Communications Officer 781.222.6168
amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Charles River Laboratories (NYSE:CRL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024